News
diabetic macular edema
Regeneron receives FDA approval for EYLEA HD
The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.
AMD
FDA approves Izervay for treatment of geographic atrophy
The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
anti-VEGF
New anti-VEGF therapy shows promise in Phase 1 Clinical trial
The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy.
AMD
AI algorithm may be a helpful tool for determining progression of AMD
Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.
age-related macular degeneration
Anti-VEGF treatment for wet AMD may hasten progression of glaucoma
Researchers concluded that anti-VEGF treatments do raise the risk of glaucoma progression.
AMD
One neovascular AMD treatment more effective than the other
A recent study reveals that one anti-VEGF treatment is more effective than another commonly used treatment.
AMD
Eye implant to treat wet macular degeneration approved by FDA
The device is the size of a grain of rice and is refilled every six months.
age-related macular degeneration
Study indicates some patients may be "weaned" off injections for wet macular degeneration
Study results offer hope to patients with wet macular degeneration who are receiving anti-VEGF injections.
age-related macular degeneration
Gene Therapy for Macular Degeneration positive results
For patients suffering from age-related macular degeneration, gene therapy has the potential to transfigure the treatment options that are available.